

Media Release

Ad hoc announcement pursuant to Art. 53 LR

SHL Telemedicine enters into Agreement with CVS Pharmacy Inc. for use of SmartHeart™ full 12 lead ECG technology

Tel Aviv / Zurich – 18 October 2021 – SHL Telemedicine Ltd. today announced that it has entered into a Purchase and Service Agreement with CVS Pharmacy Inc, according to which SHL will provide SmartHeart[™] 12 Lead ECG unit and technology for the delivery of ECGs and related services at select MinuteClinic locations for use in its clinical and patient care protocols.

"We are very pleased to enter into this collaboration with MinuteClinic, a leading retail health clinic in the US market. Our unique FDA-approved and patented SmartHeart™ technology for performing full 12 Lead ECG fits well with the health care services offered at MinuteClinic," said Erez Nachtomy, CEO of SHL Telemedicine. "This is a meaningful step up for SHL's activity in the US, as we continue to pursue and implement our strategy for fast growth in the US market."

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.